Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network

Of 319 children with invasive candidiasis, 67 (21%) transitioned from intravenous to enteral antifungal therapy. Eight (12%) transitioned back to intravenous antifungal therapy, one due to perceived treatment failure defined by clinical progression or worsening. Global treatment response at study completion was successful in 66 participants who transitioned to enteral therapy.

Authors

Institutions

Publication Details

Journal
Journal of the Pediatric Infectious Diseases Society
Published
2024-11-08
DOI
https://doi.org/10.1093/jpids/piae116
Citations
1
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
0.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network

Christine M. Salvatore, Pere Soler‐Palacín, Irja Lutsar, Elio Castagnola et al.
1 citations
Journal of the Pediatric Infectious Diseases Society
Antifungal resistance and susceptibility
0.39
article

Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network

Christine M. Salvatore, Pere Soler‐Palacín, Irja Lutsar, Elio Castagnola, Elizabeth D Knackstedt, Natasha Halasa, Arunaloke Chakrabarti, Robert Bucayu, Fabianne Altruda de Moraes Costa Carlesse, Dawn Nolt, İnci Yıldırım, Sadie Johnson, Emmanuel Roilides, Jose Rafael Romero, Antonio Arrieta, Surabhi B Vora, Rachel L Wattier, Monica I. Ardura, Blanca E. Gonzalez, Brian T. Fisher, William J. Steinbach, David M. Berman, William J. Muller, Tanvi S Sharma, Martha Avilés-Robles, Dwight E. Yin, Gabriela Marón, Craig L K Boge, Kiran Belani, Lara Danziger‐Isakov, Alison C. Tribble, Daniel E. Dulek, Anna R. Huppler, Lillian Sung, Catherine C. Aftandilian, Michael Green, Eduardo López‐Medina, Sujatha Rajan, Debra L. Palazzi, Alice Pong, Mark J. Abzug
article en
1 citations

Abstract

Of 319 children with invasive candidiasis, 67 (21%) transitioned from intravenous to enteral antifungal therapy. Eight (12%) transitioned back to intravenous antifungal therapy, one due to perceived treatment failure defined by clinical progression or worsening. Global treatment response at study completion was successful in 66 participants who transitioned to enteral therapy.

Journal of the Pediatric Infectious Diseases SocietyVol. 13(12)
Northwestern University (US), Children's Hospital of Wisconsin (US), Cincinnati Children's Hospital Medical Center (US), Boston Children's Hospital (US), Centers for Disease Control and Prevention (US), Lurie Children's Hospital (US), Seattle Children's Hospital (US), Monroe Carell Jr. Children's Hospital (US), Children's Hospital of Orange County (US), St. Jude Children's Research Hospital (US), Nationwide Children's Hospital (US), Cleveland Clinic (US), Children's Hospital of Philadelphia (US), Harvard University (US), Oregon Health & Science University (US), University of California, San Francisco (US), Baylor College of Medicine (US), National Center for Immunization and Respiratory Diseases (US), University of Washington (US), University of California, Irvine (US), Medical College of Wisconsin (US), Cornell University (US), Aristotle University of Thessaloniki (GR), University of Utah (US), University of Michigan (US), Cleveland Foundation (US), Hospital for Sick Children (CA), Istituto Giannina Gaslini (IT), University of Utah Hospital (US), Yale University (US), University of California San Diego (US), Rady Children's Hospital-San Diego (US), Support group for adolescents and children with cancer (BR), Children's Hospital Colorado (US), Hospital Infantil de México Federico Gómez (MX), Sisters of Mercy Health System (US), Burn Institute (US), Cohen Children's Medical Center (US), Yale New Haven Health System (US), Vall d'Hebron Hospital Universitari (ES), Children's Hospital of Pittsburgh (US), Children's Minnesota (US), Texas Children's Hospital (US), C. S. Mott Children's Hospital (US), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Doernbecher Children's Hospital (US), Hippocration General Hospital (GR), Weill Cornell Medicine (US), The Ohio State University (US), University of Tartu (EE), University of Cincinnati (US), University of Missouri–Kansas City (US), University of Pennsylvania (US), University of Arkansas for Medical Sciences (US), Universidade Federal de São Paulo (BR), Vanderbilt University Medical Center (US), Universidad del Valle (CO), University of Colorado Denver (US), Stanford University (US)
U.S. Department of Health and Human Services, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Melinta Therapeutics, Amplyx, Nabriva Therapeutics, Moderna, Astellas Pharma, Shionogi, SymBio Pharmaceuticals Limited, Seqirus, National Institutes of Health, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, Allergan, Sanofi Pasteur, National Institute of Allergy and Infectious Diseases, Janssen Biotech
Good health and well-being
Openalex Percentile: Top 35%
Antifungal resistance and susceptibility
0.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.